Diffuse Large B-Cell Lymphoma: Clinical Presentation and Treatment Outcomes From the OncoCollect Lymphoma Registry

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) is the commonest subtype of lymphoma, standard CHOP was the treatment of choice, 42% of patients received rituximab, and 29% of patients were lost to follow-up during therapy, were reported in a study that collected retrospective data at 13 public an...

Descripción completa

Detalles Bibliográficos
Autores principales: Nair, Reena, Bhurani, Dinesh, Rajappa, Senthil, Kapadia, Asha, Reddy Boya, Rakesh, Sundaram, Subramanian, Menon, Hari, Raman, Ganapathi S., Seshachalam, Arun, Nimmagadda, Ramesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847307/
https://www.ncbi.nlm.nih.gov/pubmed/35186714
http://dx.doi.org/10.3389/fonc.2021.796962

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847307/
https://www.ncbi.nlm.nih.gov/pubmed/35186714
http://dx.doi.org/10.3389/fonc.2021.796962

Ejemplares similares